Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

By L. Harris, Nofisat Ismaila, Lisa M. McShane, F. André, Deborah E Collyar, A. González-Angulo, Elizabeth H. Hammond, N. Kuderer, Minetta C Liu, R. Mennel and 3 more. Journal of Clinical Oncology, 2016

711 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/44e7bab4523d86a8505fd177271c1b50fb47fec9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017, background): “The Ki67 labeling index as a single marker of proliferation was not considered sufficiently reliable to add to staging because of its known lack of reproducibility, especially between different laboratories, as well as the lack of agreement on an optimal cutoff point.(14,23) The staging complexity o”
Genomic Evolution of Breast Cancer Metastasis and Relapse (2017, background): “Gene expression profiles classify breast cancers into different subtypes, with clinical trials showing that these transcriptional signatures can be used to support therapeutic decisions in primary breast cancer (Harris et al., 2016).”
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018, background): “There was considerable discussion concerning the indication for gene expression signatures [22].”